Non-Small Cell Lung Cancer Market Size, Growth 2034

Non-Small Cell Lung Cancer Market - By Type, By Treatment, By Gender, By End Use - Global Forecast, 2025 - 2034

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Data mining sources

1.3.1&nbsp;&nbsp;&nbsp; Global

1.3.2&nbsp;&nbsp;&nbsp; Regional/country

1.4&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.4.1&nbsp;&nbsp;&nbsp; Base year calculation

1.4.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.6&nbsp;&nbsp;&nbsp; Forecast model

1.7&nbsp;&nbsp;&nbsp; Research assumption and limitations

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary 

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

2.2&nbsp;&nbsp;&nbsp; Key market trends

2.2.1&nbsp;&nbsp;&nbsp; Regional

2.2.2&nbsp;&nbsp;&nbsp; Type

2.2.3&nbsp;&nbsp;&nbsp; Treatment

2.2.4&nbsp;&nbsp;&nbsp; Gender

2.2.5&nbsp;&nbsp;&nbsp; End use

2.3&nbsp;&nbsp;&nbsp; CXO perspectives: Strategic imperatives

2.3.1&nbsp;&nbsp;&nbsp; Key decision points for industry executives

2.3.2&nbsp;&nbsp;&nbsp; Critical success factors for market players

2.4&nbsp;&nbsp;&nbsp; Future outlook and strategic recommendations

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights 

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.1.1&nbsp;&nbsp;&nbsp; Supplier landscape

3.1.2&nbsp;&nbsp;&nbsp; Value addition at each stage

3.1.3&nbsp;&nbsp;&nbsp; Factor affecting the value chain

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing prevalence of non-small cell lung cancer

3.2.1.2&nbsp;&nbsp;&nbsp; Breakthroughs in immunotherapy and targeted treatments

3.2.1.3&nbsp;&nbsp;&nbsp; Advancements in diagnostic technologies

3.2.1.4&nbsp;&nbsp;&nbsp; Growing adoption of personalized medicine

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High cost of advanced therapies

3.2.2.2&nbsp;&nbsp;&nbsp; Regulatory and diagnostic infrastructure gaps

3.2.3&nbsp;&nbsp;&nbsp; Market opportunities

3.2.3.1&nbsp;&nbsp;&nbsp; Rising demand in emerging markets

3.2.3.2&nbsp;&nbsp;&nbsp; Shift toward personalized and combination therapies

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.4.1&nbsp;&nbsp;&nbsp; North America

3.4.2&nbsp;&nbsp;&nbsp; Europe

3.4.3&nbsp;&nbsp;&nbsp; Asia Pacific

3.4.4&nbsp;&nbsp;&nbsp; Latin America

3.4.5&nbsp;&nbsp;&nbsp; Middle East and Africa

3.5&nbsp;&nbsp;&nbsp; Future market trends

3.6&nbsp;&nbsp;&nbsp; Pipeline analysis

3.7&nbsp;&nbsp;&nbsp; Technology and innovation landscape

3.8&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.9&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2024

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.3&nbsp;&nbsp;&nbsp; Company matrix analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Key developments

4.6.1&nbsp;&nbsp;&nbsp; Merger and acquisition

4.6.2&nbsp;&nbsp;&nbsp; Partnership and collaboration

4.6.3&nbsp;&nbsp;&nbsp; New product launches

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Adenocarcinoma

5.3&nbsp;&nbsp;&nbsp; Squamous cell carcinoma

5.4&nbsp;&nbsp;&nbsp; Large cell carcinoma

5.5&nbsp;&nbsp;&nbsp; Other types

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Treatment, 2021 - 2034 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Chemotherapy

6.3&nbsp;&nbsp;&nbsp; Immunotherapy

6.4&nbsp;&nbsp;&nbsp; Targeted therapy

6.5&nbsp;&nbsp;&nbsp; Other treatment types

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Male

7.3&nbsp;&nbsp;&nbsp; Female

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Hospitals

8.3&nbsp;&nbsp;&nbsp; Specialty clinics

8.4&nbsp;&nbsp;&nbsp; Other end use

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Netherlands

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; China

9.4.2&nbsp;&nbsp;&nbsp; Japan

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Argentina

9.6&nbsp;&nbsp;&nbsp; Middle East and Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; UAE

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles 

10.1&nbsp;&nbsp;&nbsp; AbbVie

10.2&nbsp;&nbsp;&nbsp; Astellas Pharma

10.3&nbsp;&nbsp;&nbsp; AstraZeneca

10.4&nbsp;&nbsp;&nbsp; Bristol-Myers Squibb Company

10.5&nbsp;&nbsp;&nbsp; Eli Lilly

10.6&nbsp;&nbsp;&nbsp; F. Hoffmann La Roche

10.7&nbsp;&nbsp;&nbsp; Janssen Biotech

10.8&nbsp;&nbsp;&nbsp; Merck &amp; Co.

10.9&nbsp;&nbsp;&nbsp; Merus

10.10&nbsp;&nbsp;&nbsp; Novartis

10.11&nbsp;&nbsp;&nbsp; Pfizer

10.12&nbsp;&nbsp;&nbsp; Sanofi

10.13&nbsp;&nbsp;&nbsp; Sun Pharmaceutical

10.14&nbsp;&nbsp;&nbsp; Takeda

10.15&nbsp;&nbsp;&nbsp; Xcovery

&nbsp;&nbsp;&nbsp;

Non-Small Cell Lung Cancer Market

Inquiry Before Buying